JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $140

Benzinga Newsdesk www.benzinga.com Positive 76.5%

Neg 0% Neu 0% Pos 76.5%

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $135 to $140.